Health
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 | NEJM – nejm.org
Correspondence from The New England Journal of Medicine — SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
We conducted a global, randomized, placebo-controlled, phase 123 pivotal trial in which two 30-g doses of BNT162b2 (PfizerBioNTech) were administered 21 days apart (ClinicalTrials.gov number, NCT04368728). These doses of vaccine had mainly low-grade side…
Continue Reading
-
General13 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General13 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News22 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General13 hours agoOf saints and sinners | The Spectator Australia